Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
MWN-AI** Summary
Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), an Australian pharmaceutical company dedicated to creating therapies for pancreatic cancer, is set to present at the Life Sciences Investor Forum on March 12, 2026. CEO Dr. Chris Burns will lead the presentation, scheduled for 3:30 – 4:00 pm EDT (March 13, 6:30 – 7:00 am AEDT), allowing investors and industry professionals to engage in real-time discussions.
The forum, hosted by VirtualInvestorConferences.com, offers an interactive online platform for stakeholders to submit questions and gain insights into Amplia's ongoing projects. Investors are encouraged to pre-register and ensure they have operational checkups on the online system to enhance their experience. Replays of the event will also be accessible after its conclusion.
Amplia's recent advancements include impressive clinical data from the ACCENT trial of its drug narmafotinib, a Focal Adhesion Kinase (FAK) inhibitor. The trial has demonstrated a confirmed overall response rate (ORR) of 42% and a median progression-free survival (mPFS) of 7.7 months when combined with standard chemotherapy in advanced pancreatic cancer patients. Additionally, Amplia has expanded its clinical trials with the opening of new sites in the US and alignment with the FDA for a planned Phase 2b/3 trial.
Narmafotinib (AMP945) has emerged as a promising candidate in targeting pancreatic and fibrotic cancers due to its selective inhibition of FAK, a protein linked to solid tumors. Amplia’s commitment to advancing its pipeline emphasizes the growing importance of FAK in oncology.
For more details on attending the Investor Forum or for company specifics, interested parties can visit Amplia's official website and Virtual Investor Conferences.
MWN-AI** Analysis
As Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) prepares to present at the Life Sciences Investor Forum on March 12, 2026, investors should closely monitor the developments surrounding its lead drug candidate, narmafotinib, particularly given its implications for the treatment of pancreatic cancer. This presentation represents a significant opportunity for Amplia to share progress on its clinical trials and engage with potential investors.
Recent updates highlight impressive results from the ACCENT trial, where narmafotinib demonstrated an overall response rate (ORR) of 42% and a median progression-free survival (mPFS) of 7.7 months—outcomes that outperform the benchmark set by conventional therapies. The strategic alignment with the FDA on the upcoming registrational Phase 2b/3 trial indicates a favorable regulatory pathway, which could catalyze investor confidence moving forward.
Investors should take note of the expanding clinical footprint, with new sites opened in the United States for the AMPLICITY trial, exploring the combination of narmafotinib with FOLFIRINOX. The market may respond positively to Amplia’s innovative approach in addressing a critical need for effective therapies in a challenging oncology space.
Given these factors, Amplia's stock could see volatility related to trial results and presentation feedback. Maintaining a watchful eye on the outcomes from the ongoing trials and Dr. Chris Burns' engagement at the forum will be essential for gauging the company’s market potential.
Long-term investors might consider adding Amplia as a speculative play based on its robust pipeline and clinical advancements, while monitoring updates from the investor forum for insights and guidance directly from company management. Overall, a cautious yet optimistic posture may serve investors well as Amplia navigates the complexities of drug development in the oncology sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELBOURNE, Australia, March 11, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), focused on the development of drugs for pancreatic cancer, today announced that CEO and Managing Director Dr. Chris Burns, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th (US time)/March 13th (AU time), 2026.
DATE: March 12th (US)/ March 13th (AU)
TIME: 3:30 – 4:00 pm US EDT; 6:30 – 7:00 am AEDT
Available for 1x1 meetings: March 12-17. Schedule 1x1 Meetings here.
The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights
- Updated ORR of 42% and mPFS of 7.7 mo in ACCENT trial of narmafotinib in metastatic pancreatic cancer
- Opening of US sites in second pancreatic cancer trial
- Alignment with FDA on structure of planned registrational Phase 2b/3 trial
- Compelling preclinical data highlighting clinical potential of narmafotinib combination with kRAS inhibitors in pancreatic and other cancers
| Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com U.S. Contact: Robert Giordano rjgiordano@ggrouplifesciences.com +1 917 327 3938 | Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 U.S. Media: media@ampliatx.com |
About Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn.
About Narmafotinib
Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumors. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the ACCENT trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has already achieved its primary endpoint in achieving a confirmed response rate of 35%, superior to 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone. An interim median PFS of 7.7 months has also been reported. A second trial – AMPLICITY – has recently opened and is being run under an IND at sites in Australia and the US, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
FAQ**
How does Amplia Therapeutics Ltd INNMF plan to leverage the updated ORR of 42% and mPFS of 7.7 months in the ACCENT trial to attract potential investors during the upcoming Life Sciences Investor Forum?
What specific strategies will Amplia Therapeutics Ltd INNMF implement to capitalize on the promising preclinical data regarding narmafotinib's combination with kRAS inhibitors in its ongoing clinical trials?
Can you provide insights into how the alignment with the FDA regarding the registrational Phase 2b/3 trial of Amplia Therapeutics Ltd INNMF may influence future funding opportunities and investor interest?
How does Amplia Therapeutics Ltd INNMF plan to utilize the interactive format of the Virtual Investor Conferences to engage with investors and address any concerns they may have about the company’s pipeline and clinical developments?
**MWN-AI FAQ is based on asking OpenAI questions about Amplia Therapeutics Ltd (OTC: INNMF).
NASDAQ: INNMF
INNMF Trading
7.44% G/L:
$0.0967 Last:
14,277 Volume:
$0.09 Open:
